These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 22207123)

  • 1. Is lipoxins A₄ a better alternative to anti-VEGF and anti-TNF-α antibody to prevent and treat age-related macular degeneration, diabetic macular edema and retinopathy?
    Das UN
    Med Sci Monit; 2012 Jan; 18(1):LE1-2. PubMed ID: 22207123
    [No Abstract]   [Full Text] [Related]  

  • 2. Is lipoxins A4 a better alternative to anti-TNF-alpha antibody to prevent and treat diabetic macular edema and retinopathy?
    Das UN
    Med Sci Monit; 2010 Sep; 16(9):LE13-4. PubMed ID: 20802423
    [No Abstract]   [Full Text] [Related]  

  • 3. Lipoxins, resolvins, and protectins in the prevention and treatment of diabetic macular edema and retinopathy.
    Das UN
    Nutrition; 2013 Jan; 29(1):1-7. PubMed ID: 22677359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VEGF inhibitors for AMD and diabetic macular edema.
    Med Lett Drugs Ther; 2015 Mar; 57(1464):41-2. PubMed ID: 25758545
    [No Abstract]   [Full Text] [Related]  

  • 5. [New drug VEGF Trap-Eye--Eylea--and its use in the treatment of age-related macular degeneration, central retinal vein occlusion, diabetic macular edema, and choroidal neovascularization secondary to pathologic myopia].
    Rejdak R; Szkaradek M; Taslaq W; Kałuzny JJ; Grieb P; Jünemann AG
    Klin Oczna; 2012; 114(4):308-10. PubMed ID: 23461161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema.
    Emerson MV; Lauer AK
    BioDrugs; 2007; 21(4):245-57. PubMed ID: 17628122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [What can anti-VEGF therapy achieve in clinical routine? : Effectiveness of anti-VEGF therapy in patients with macular diseases in clinical routine on 1492 eyes in Austria].
    Wiesinger K; Reinelt P; Ennemoser A; Edelmayr M; Schönherr U
    Ophthalmologe; 2017 Jul; 114(7):639-645. PubMed ID: 27815675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety monitoring with ocular anti-vascular endothelial growth factor therapies.
    Fung AE; Bhisitkul RB
    Br J Ophthalmol; 2008 Dec; 92(12):1573-4. PubMed ID: 19029158
    [No Abstract]   [Full Text] [Related]  

  • 9. Faricimab (Vabysmo) for age-related macular degeneration and diabetic macular edema.
    Med Lett Drugs Ther; 2022 Mar; 64(1646):45-46. PubMed ID: 35294428
    [No Abstract]   [Full Text] [Related]  

  • 10. Future Perspectives: Agents on the Horizon.
    Maya JR; Sadiq MA; Agarwal A; Kaiser PK; Stoller GL; Sepah YJ; Nguyen QD
    Dev Ophthalmol; 2016; 55():391-8. PubMed ID: 26501694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eyes on New Product Development.
    Novack GD
    J Ocul Pharmacol Ther; 2018 Jun; 34(5):373. PubMed ID: 29742011
    [No Abstract]   [Full Text] [Related]  

  • 12. [A Case of Diabetic Macular Edema with Improvement in Severity of Diabetic Retinopathy following Frequent Anti-Vascular Endothelial Growth Factor Treatment].
    Yoshida S; Yamana S; Inoue R; Kubo Y; Kobayashi Y; Nakama T; Sonoda KH; Ishibashi T
    Nippon Ganka Gakkai Zasshi; 2017 May; 121(5):425-30. PubMed ID: 30074752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening, prevention, and ambitious management of diabetic macular edema in patients with type 1 diabetes.
    Tarantola RM; Maturi RK; Kushal S; Gupta S
    Curr Diab Rep; 2013 Oct; 13(5):679-86. PubMed ID: 23959793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-VEGF: one drug for different conditions?].
    Cohen SY; Massin P; Souied E
    J Fr Ophtalmol; 2013 Jan; 36(1):2-4. PubMed ID: 23290491
    [No Abstract]   [Full Text] [Related]  

  • 15. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.
    Chong V
    Ophthalmologica; 2012; 227 Suppl 1():2-10. PubMed ID: 22517120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic evaluation of pegaptanib octasodium for the treatment of diabetic edema.
    Morjaria R; Chong NV
    Expert Opin Drug Metab Toxicol; 2014 Aug; 10(8):1185-92. PubMed ID: 24856361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
    Wu L; Martínez-Castellanos MA; Quiroz-Mercado H; Arevalo JF; Berrocal MH; Farah ME; Maia M; Roca JA; Rodriguez FJ;
    Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):81-7. PubMed ID: 17674014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring ocular drug therapy by analysis of aqueous samples.
    Campochiaro PA; Choy DF; Do DV; Hafiz G; Shah SM; Nguyen QD; Rubio R; Arron JR
    Ophthalmology; 2009 Nov; 116(11):2158-64. PubMed ID: 19700195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. QUANTITATIVE OPTICAL COHERENCE TOMOGRAPHY ANALYSIS OF RETINAL DEGENERATIVE CHANGES IN DIABETIC MACULAR EDEMA AND NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Boiko EV; Maltsev DS
    Retina; 2018 Jul; 38(7):1324-1330. PubMed ID: 28492427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risuteganib-a novel integrin inhibitor for the treatment of non-exudative (dry) age-related macular degeneration and diabetic macular edema.
    Shaw LT; Mackin A; Shah R; Jain S; Jain P; Nayak R; Hariprasad SM
    Expert Opin Investig Drugs; 2020 Jun; 29(6):547-554. PubMed ID: 32349559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.